Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer
Фаза 2
Прекращено
NCT05581589
| Заболевание | Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8 |
|---|
| Фаза | Фаза 2 |
|---|
| Спонсор | University of Washington |
|---|
| Статус | Прекращено |
|---|
| Участники | 4 участн. |
|---|
| Вмешательство | Lymphadenectomy, Radical Cystectomy, Sacituzumab Govitecan |
|---|
| Дата начала | 15.06.2023 |
|---|
| Дата завершения | 15.10.2024 |
|---|
| Публикация результатов | 27.04.2026 |
|---|
Кратко
This phase II trial tests whether sacituzumab govitecan given before radical cystectomy works in treating patients with non-urothelial bladder cancer. Sacituzumab govitecan contains a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as TROP2 receptors, and delivers govitecan to kill them. Giving sacituzumab govitecan before radical cystectomy may make the surgery more effective in patients with muscle invasive bladder cancer.
Pathologic Complete Response (pCR Defined as ypT0N0)
At radical cystectomy (Radical cystectomy is expected to occur within 2-6 weeks after the last neoadjuvant trial therapy dose) · Participants
| Treatment (Sacituzumab Govitecan) | 1 Participants |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.